title: Left ventricular assist devices: a kidney's perspective.
abstract: The left ventricular assist device (LVAD) has become an established treatment option for patients with refractory heart failure. Many of these patients experience chronic kidney disease (CKD) due to chronic cardiorenal syndrome type II, which is often alleviated quickly following LVAD implantation. Nevertheless, reversibility of CKD remains difficult to predict. Interestingly, initial recovery of GFR appears to be transient, being followed by gradual but significant late decline. Nevertheless, GFR often remains elevated compared to preimplant status. Larger GFR increases are followed by a proportionally larger late decline. Several explanations for this gradual decline in renal function after LVAD therapy have been proposed, yet a definitive answer remains elusive. Mortality predictors of LVAD implantation are the occurrence of either postimplantation acute kidney injury (AKI) or preimplant CKD. However, patient outcomes continue to improve as LVAD therapy becomes more widespread, and adverse events including AKI appear to decline. In light of a growing destination therapy population, it is important to understand the cumulative effects of long-term LVAD support on kidney function. Additional research and passage of time are required to further unravel the intricate relationships between the LVAD and the kidney.
authors: University Medical Center Utrecht, POB 85500, 3508 GA, Utrecht, The Netherlands, T.R.T.M.Tromp@students.uu.nl.
authors: T R
authors: TR
authors: Tromp
authors: N
authors: N
authors: de Jonge
authors: J A
authors: JA
authors: Joles
mesh_terms: D000818:Animals; D059347:Cardio-Renal Syndrome / Q000503:physiopathology; D006333:Heart Failure / Q000601:surgery*; D006353:Heart-Assist Devices / Q000009:adverse effects*; D006801:Humans; D007668:Kidney / Q000503:physiopathology; D051436:Renal Insufficiency, Chronic / Q000209:etiology* / Q000503:physiopathology; D016277:Ventricular Function, Left